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O B J E C T I V E S This study sought to develop magnetic resonance contrast agents based on
high-density lipoprotein (HDL) nanoparticles to noninvasively visualize intraplaque macrophages and
collagen content in mouse atherosclerotic plaques.
B A C KG ROUND Macrophages and collagen are important intraplaque components that play central roles
in plaque progression and/or regression. In a Reversa mouse model, plaque regression with compositional
changes (from high macrophage, low collagen to low macrophage, high collagen) can be induced.
METHOD S This study labeled HDL nanoparticles with amphiphilic gadolinium chelates to enable target-
speciﬁc imaging of intraplaque macrophages. To render HDL nanoparticles speciﬁc for the extracellular matrix,
labeled HDL nanoparticles were functionalized with collagen-speciﬁc EP3533 peptides (EP3533-HDL) via poly(eth-
ylene glycol) spacers embedded in the HDL lipid layers. The association of nanoparticles with collagen was
examined in vitro by optical methods. The in vivo magnetic resonance efﬁcacy of these nanoparticles was
evaluated in a Reversa mouse model of atherosclerosis regression. Ex vivo confocal microscopy was applied to
corroborate the in vivo ﬁndings and to evaluate the fate of the different HDL nanoparticles.
R E S U L T S All nanoparticles had similar sizes (10  2 nm) and longitudinal relaxivity r1 (9  1 s
1
mmol/l1). EP3533-HDL showed strong association with collagen in vitro. After 28 days of plaque
regression in Reversa mice, EP3533-HDL showed signiﬁcantly increased (p  0.05) in vivo magnetic
resonance signal in aortic vessel walls (normalized enhancement ratio [NERw]  85  25%; change of
contrast-to-noise ratio [∆CNRw]  17  5) compared with HDL (NERw  7  23%; ∆CNRw  2  4)
and nonspeciﬁc control EP3612-HDL (NERw  4  24%; ∆CNRw  1  6) at 24 h after injection. Ex vivo
confocal images revealed the colocalization of EP3533-HDL with collagen. Immunohistostaining analysis
conﬁrmed the changes of collagen and macrophage contents in the aortic vessel walls after regression.
CONCLUSIONS This study shows that the HDL nanoparticle platform can bemodiﬁed tomonitor in vivo plaque
compositional changes in a regression environment, which will facilitate understanding plaque regression and the
search for therapeutic interventions. (J Am Coll Cardiol Img 2013;6:373–84) © 2013 by the American College of
Cardiology Foundation
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374therosclerotic plaques are the result of a
chronic inflammatory response in arterial
vessel walls to the accumulated lipoproteins
that contain apolipoprotein B (1). The
rupture of a plaque may cause many severe health
risks (2–4). Active inflammation with extensive
macrophage infiltration into vessel walls, leading to
plaques with a thin fibrous cap and a large lipid
necrotic core are considered to be the major indi-
cators, among several other factors, for high-risk
plaques prone to rupture (5–11).
One of the therapeutic intervention goals for
high-risk patients is to stabilize atherosclerotic le-
sions by inducing regression. In clinical studies, the
stabilization of plaques has been found to correlate
with lower intraplaque macrophages and higher
interstitial collagen (12). Pre-clinical animal studies
have further facilitated the understanding of plaque
regression (12–15). Recently, the Fisher and Young
groups developed the Reversa mouse model that
possesses 4 homozygous alleles, LDLR/
ApoB100/100Mttpfl/flMx1-Cre/ (16).
When microsomal triglyceride transfer
protein is conditionally ablated after
plaque formation, low-density lipoprotein
production falls, and the hyperlipide-
mic plasma profile abates, with a conse-
quent regression of disease as indicated by
a decrease of macrophages and increase of
collagen in plaques (17). Although these
changes in plaque component levels dur-
ing regression have been confirmed by ex
vivo histological examinations, noninva-
sive in vivo visualization methods to detect
these biological events by molecular imaging are
highly desired to allow temporal evaluation of the
stabilization of atherosclerosis.
Magnetic resonance (MR) imaging is one of
the most powerful techniques to noninvasively
visualize plaque composition and biological activ-
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However, contrast agents with high payload are
often essential for molecular MR imaging due to
the low concentration of biomarkers and inher-
ently low sensitivity of MR (20,21). We have
previously developed high-density lipoprotein
(HDL)-based MR contrast agents to evaluate
intraplaque macrophage content via their natural
affinity for plaque macrophages (22–26). In this
study, we report the use of HDL-based MR
contrast agents to visualize 2 key plaque compo-
nents: macrophages and collagen during plaque
regression conditions in Reversa mice. The HDL
platform was used because of its endogenous
nature, small size (10 nm) that allows penetra-
tion into atherosclerotic plaques, and the possi-
bility to include a higher contrast payload than
small molecule platforms could. In addition,
because plaque component changes in the dura-
tion of this study are more evident than size
changes are (13,16,17), we were able to focus on
changes in composition.
M E T H O D S
Materials. The collagen-specific peptide EP-3533
ith the sequence GKWH[CTTKFPHHYC]
YBip-CONH2, and the nonspecific peptide EP-
3612 containing non-natural D-Cys as shown in
Figure 1 were synthesized by Peptide International
(Louisville, Kentucky). 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sul-
fonyl) (Avanti Polar Lipids, Inc., Alabaster, Alabama)
and gadolinium diethylenetriaminepentaacetate-
bis(stearylamide) (iQSynthesis, St. Louis, Missouri)
were used as fluorescence label and MR contrast
agents, respectively. The preparation of HDL
nanoparticles followed our previous methods
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375(22–26), but we included 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[carboxy(polyethylene
glycol)-2000] ammonium salt (Avanti Polar Lip-
ids, Inc.) to allow the peptides to attach.
PREPARATION OF EP3533-HDL AND EP3612-HDL
NANOPARTICLES. The conjugation of EP-3533 pep-
ides to HDL nanoparticles is schematically illustrated in
igure 1. First, the HDL nanoparticles were transferred
nto 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
cid buffer (pH  5.0) and reacted with 1-ethyl-3-
3-dimethylaminopropyl]carbodiimide hydrochlo-
ide and N-hydroxysuccinimide. After incubation at
oom temperature for 2 h, the reaction solution was
horoughly washed. Then 1 mg/ml EP-3533 pep-
ides in dimethyl sulfoxide was added into the
olution with a 1:1.1 1,2-distearoyl-sn-glycero-3-
hosphoethanolamine-N-[carboxy(polyethylene
lycol)-2000] ammonium salt/EP-3533 molar ratio.
his preparation was kept at room temperature for 4 h,
Figure 1. Chemical Structures and Experiment Design
Illustration of (A) method to functionalize high-density lipoprotein
EP3533-HDL) and (B) animal experiment design. apo A-I  apolipop
DSPC-PEG-COOH  1,2-distearoyl-sn-glycero-3-phosphoethanolamin
1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride; GD-D
ide); MRI  magnetic resonance imaging; NHS  N-hydroxysuccinim
DMPC  1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-(lissatored at 4°C overnight, and then purified and bufferxchanged to phosphate-buffered saline (PBS). The final
anoparticles were named EP3533-HDL.
Nonspecific control nanoparticles (EP3612-
DL) were prepared by the same procedure using
P-3612 peptides.
IN VITRO BINDING ASSAY. Black 96-well plates
ere incubated with different proteins overnight
t 4°C and then washed with PBS. After blocking
ith 2% bovine serum albumin (BSA) for 3 h at
7°C, they were washed again with PBS. Then
anoparticles were added to each well and incu-
ated 3 h at 37°C. After cooling to room tem-
erature, the total fluorescence I0 of nanoparticles
as recorded (excitation: 540  25 nm; emission:
90  35 nm). Then the nanoparticle solutions
ere aspirated. The plates were washed 3 times
ith PBS, after which the binding fluorescence
bind was recorded. The average fluorescence
eading of empty wells Iempty was subtracted from
) nanoparticles with collagen-speciﬁc EP3553 peptides (named as
ein A-I; DPPC  1,2-Dipalmitoyl-sn-glycero-3-phosphocholine;
-[carboxy(polyethylene glycol)-2000] ammonium salt; EDC 
-DSA  gadolinium diethylenetriaminepentaacetate-bis(stearylam-
; pIpC  polyinsinic-polycytidylic ribonucleic acid; rhodamine-
e rhodamine B sulfonyl).(HDL
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376fluorescence labeling of 1,2-dimyristoyl-sn-
glycero-3-phosphoethanolamine-N-(lissamine
hodamine B sulfonyl)from nanoparticles during
eptide conjugation, the binding of nanoparticles
as normalized as Normalized Binding  (Ibind –
empty)/(I0 – Iempty)*[Gd].
ANIMAL USE. The Institutional Animal Care and
se Committee of Mount Sinai School of Med-
cine approved the animal protocols and proce-
ures. At 4 weeks of age, Reversa mice were
eaned and then fed on Western diet containing
0.15% cholesterol and 21% fat for 16 weeks.
ice were then divided into “regression” and
ontrol groups as shown in Figure 1. The regres-
ion group was fed on a chow diet and Cre was induced
y intraperitoneal injection of polyinosinic-polycytidylic
ibonucleic acid (250 g every other day for a total of 4
njections). Day 0 was defined as the ninth day after first
olyinosinic-polycytidylic ribonucleic acid injection. The
ice were scanned by MR imaging at day 0 (n 5) and
ay 28 (n  5) and then sacrificed for histological
taining. The control group was fed the Western diet for
he duration of the experiment and injected with saline.
MR IMAGING. The animals underwent in vivo
R imaging of the abdominal aorta using a
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Figure 2. In Vitro Binding of Nanoparticles
Normalized in vitro binding of (A) high-density lipoprotein (HDL), (B
different proteins..4-T, 89-mm bore magnet system. High-
esolution T1-weighted images were generated
sing a black blood spin echo sequence (repeti-
ion time/echo time  800 ms/8.6 ms, field of
iew  3.0  3.0 cm, matrix size  256  256,
22 contiguous 500 m-thick axial slices, number
f averages  16, total scan time  54 min).
fter pre-injection imaging, the animals were
dministered a nanoparticle contrast agent (50mol
of Gd/kg) via the tail vein. Post-injection imaging with
the same parameters was performed on each animal at
24 h after injection. The slices of the post-injection scan
were matched to the pre-injection scan by using unique
vertebral and paraspinous muscular anatomy as
landmarks.
IMMUNOHISTOCHEMISTRY. Frozen abdominal
aorta sections were stained using as primary
antibodies either rat antimouse CD68 (Serotec,
Raleigh, North Carolina) or rabbit antimouse
collagen I (COL1A2:M-80, Santa Cruz Biotech-
nology Inc., Dallas, Texas). The secondary anti-
body was Alexa Fluor 647 conjugated goat antirat
Ab or Alexa Fluor 647 conjugated goat antirabbit
Ab (Serotec) corresponding to the primary anti-
body. Confocal imaging was performed using a
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377Leica SP5DM microscope (Buffalo Grove,
Illinois).
Frozen sections were stained by Sirius red (Poly-
sciences, Warrington, Pennsylvania) to detect inter-
stitial collagen using birefringency illumination
with polarized light.
For immunohistochemical CD68 staining, the
frozen sections were stained using a rat antimouse
CD68 primary antibody (Serotec). The sections
were visualized using Vector Red solution for
positive areas and counterstained blue with Vec-
tor Hematoxylin QS (Vector Laboratories, Inc.,
Burlingame, California).
IMAGE ANALYSIS. For in vivo MR images, the signal-
o-noise ratio (SNR) of the region of interest (ROI) is
efined by SNRROI  IROI/Inoise, where IROI is the
ntensity of either aortic vessel wall (SNRw) or surround-
ing muscle (SNRm); Inoise is the standard deviation
Figure 3. In Vivo MR Images of Regressed Plaques
(A) Typical MR images, (B) NERw, and (C) ∆CNRw of abdominal atheroscle
EP3612-HDL at day 0 (yellow bars) and day 28 (green bars) of Reversa m
represent mean  SD. The asterisks (*) indicate statistical signiﬁcance at p
NER  normalized enhancement ratio; w  aortic vessel wall; other abbreviatutside the animal. The contrast-to-noise ratio
CNR) from the aortic wall to muscle is defined
s CNRw  SNRw – SNRm. The difference of
NRw between pre- and post-injection is defined
as CNRw  (CNRw)post – (CNRw)pre. The
normalized enhancement ratio (NER) of aortic
wall to muscle is defined as NERw  [(SNRw/
NRm)p o s t – (SNRw/SNRm)p r e] / (SNRw/
SNRm)pre  100%. For ex vivo microscopy im-
ages, the percentages of positive area for
macrophage and collagen contents were analyzed
in ImageJ (W. S. Rasband, National Institutes of
Health, Bethesda, Maryland) as described in the
Online Appendix.
STATISTICS. The detailed statistical methods are
described in the Online Appendix. A value of p 
0.05 was considered statistically significant.
plaques for pre- and 24 h post-injection of HDL, EP3533-HDL, and
n the regression group. The arrows point to the aortas. The error bars
.05 (n  5 mice  5 slices/mice  25). CNR  contrast-to-noise ratio;rotic
ice i
 0ions as in Figure 1.
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378R E S U L T S
EP3533-HDL nanoparticles showed higher association
with collagen in vitro than in control group. The conju-
gation of EP3533 or EP3612 peptides to HDL via
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[carboxy(polyethylene glycol)-2000] ammonium
salt linkers did not significantly change the nano-
particle size (10  2 nm) or longitudinal relaxivity
(9  1 s–1 mmol/l–1). Figure 2A showed the
unmodified HDL had negligible and lowest in vitro
association with all the tested proteins among all 3
types of nanoparticles. EP3533-HDL (Fig. 2B),
however, had significantly higher levels of bind-
ing to collagen in comparison with HDL and
nonspecific EP3612-HDL and a low level of
association to other extracellular matrix compo-
nents, such as heparin, fibronectin, chondroitin
sulfate A, and chondroitin sulfate B. The non-
Figure 4. In Vivo MR Images of Control Plaques
(A) Typical MR images, (B) NERw, and (C) ∆CNRw of abdominal athe
HDL, and EP3612-HDL at days 0 and 28 of Reversa mice in the con
Figures 1 and 3.specific EP3612-HDL (Fig. 2C) had much lower
levels of association to all the tested collagen and
other extracellular matrix components in compar-
ison with EP3533-HDL, but slightly higher ones
than unmodified HDL.
EP3533-HDL enhanced in vivoMR signal of aortic walls of
regressing atherosclerotic plaques in Reversamice. Rep-
resentative in vivo MR images of atherosclerotic
plaques of Reversa mice in the regression group are
shown in Figure 3A. At day 0, the baseline of the
regression, HDL caused enhancement of aortic
vessel walls at 24 h after injection. However,
EP3533-HDL did not cause significant enhance-
ment. Nonspecific EP3612-HDL injection also
induced signal enhancement of MR images of
aortic vessel walls. The NERw for HDL, EP3533-
HDL, and EP3612-HDL contrast agents were
91  39%, 16  45%, and 67  37%, respectively,
at 24 h after injection (Fig. 3B). At day 28 of
lerotic plaques for pre- and 24 h post-injection of HDL, EP3533-
group (n  5 mice  5 slices/mice  25). Abbreviations as inrosc
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379regression, the signal enhancements or NERw in-
uced by the injection of HDL and EP3612-HDL
ere substantially reduced to7 23% and 4 24%,
espectively, at 24 h after injection. In comparison,
he enhancement caused by EP3533-HDL in-
reased significantly to 82  25% at 24 h after
injection (Fig. 3B). The corresponding CNRw
values are shown in Figure 3C, which showed the
ame trends as NERw. In the control group (i.e.,
ontinuing hyperlipidemia), the NERw and the
Figure 5. Colocalization of Nanoparticles
Confocal microscopy of plaques at day 28 from aortic vessel walls o
(B, D, F) collagen type I (Col I) (green) staining. The nuclei were sta
were labeled with 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamin
calization of green and red signals appeared as yellow/orange coloCNRw of all 3 nanoparticle contrast agents re- (mained similar at day 28, with values in comparison
with those at day 0 baseline (Fig. 4).
EP3533-HDL nanoparticles showed colocalization with
collagen type I in aortic vessel walls of Reversa mice at
day 28 in the regression group. After in vivo MR
maging, the colocalization of nanoparticles was
nalyzed on aortic sections at 24 h after injection of
ontrast agents. The HDL nanoparticles were
ound to localize mainly with macrophages at day
8 (Fig. 5A), in agreement with previous results
versa mice in the regression group with (A, C, E) CD68 (green) or
with 4,6-diamino-2-phenylindole (DAPI) (blue) and nanoparticles
-(lissamine rhodamine B sulfonyl) (rhodamine-PE) (red). The colo-
Scale bar: 25 m. HDL  high-density lipoprotein.f Re
ined
e-N22–25), but not with collagen type I (Fig. 5B). At
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380day 28, EP3533-HDL was found to localize with
collagen type I (Fig. 5D) with negligible association
with CD68 signal under confocal imaging (Fig.
5C). Most of the nonspecific EP3612-HDL was
not found to localize with CD68 macrophages or
ollagen type I at day 28, though some of these
anoparticles were seen at the same positions of
D68 signals in confocal images (Figs. 5E and 5F).
onfocal microscopy of all 3 types of nanoparticles
ith CD68 macrophages and collagen type I stain-
ng at day 0 is available in the Online Appendix.
The content of CD68 cells decreased at day 28 in
aortic plaques of Reversa mice in the regression
group. The area percentage of CD68 macro-
hages/foam cells (red) was 10.9  4.6% in the
laques at day 0 (Figs. 6A and 6D). At day 28 of
egression, the CD68 cells decreased significantly
o 2.6  2.0% (Figs. 6B and 6D). However, the
ontent of CD68 area increased to 15.5 5.4% at
day 28 in the control group (Figs. 6C and 6D).
The collagen content increased at day 28 in aortic
plaques of Reversa mice in the regression group. As
shown in Figure 7A, the plaques at aortic vessel
walls at day 0 showed little collagen (from analysis
of polarized light images) corresponding to a colla-
gen positive area of 2.9  2.1% (Fig. 7D). At day
Figure 6. Intraplaque Macrophage Contents
Immunohistochemical staining of CD68 macrophages (red) in the
regression and (C) control groups. Nuclei in blue. (D) The percenta
(n  5). P  plaque position.28, the collagen content increased significantly to22.1 11.6% in the regression group (Figs. 7B and
7D). However, the collagen content maintained a
similar level (2.0 0.7% of plaques) at day 28 in the
control group (Figs. 7C and 7D). The red stained
areas were observed under bright field but not
always as fibrils under polarized light in Figure 7C.
This suggests that not all the collagen was orga-
nized into fibrils but rather some was degraded by
matrix metalloproteinases expressed by macro-
phages or foam cells.
The percentage of macrophage or collagen posi-
tive area was pooled together from both the regres-
sion and control groups to establish the correlations
with in vivo MR enhancement (NERw in the aortic
alls). The correlation coefficients were 0.85 (R2 
0.71) for CD68 macrophages with in vivo NERw
from HDL injection (Fig. 8A) and 0.77 (R2 
.60) for collagen with in vivo NERw from
P3533-HDL injection (Fig. 8B).
D I S C U S S I O N
In the present study, we demonstrated that HDL-
based nanoparticles can be used as MR contrast
agents for noninvasive in vivo imaging of athero-
sclerotic plaque regression by targeting collagen
erosclerotic plaques of aorta at (A) day 0 and day 28 in (B)
f CD68 area in the plaques. The images were obtained at 40ath
ge oafter conjugation with collagen-specific EP3533
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381peptides. The interaction between HDL and colla-
gen is improved by the EP3533 peptides (Fig. 2),
which have been developed to specifically target
collagen (27). It is likely that EP3533-HDL may
bind to collagen in the media and adventitia as well
as in the plaque in vivo. Unfortunately, the resolu-
tion required to distinguish among the media,
adventitia, and plaque in mice arteries is not cur-
rently possible, although the contrast changes we
observed are most likely due to changes in collagen
in the plaque and not other parts of the arterial wall.
Macrophages and collagen play important roles
in the vulnerability of atherosclerotic plaques. Mac-
rophage content has been used to evaluate athero-
sclerotic plaque burden in animal models and in
humans (26,28–33). Feig et al. (17) reported a
detailed study of biological characteristics of Re-
versa mice, which was confirmed again in this study
(Figs. 6 and 7). In advanced plaques, collagen fibrils
re degraded by matrix metalloproteinases, resulting
n many small fragments, which were not observed
nder polarized light microscopy or seen to associ-
te with EP3533-HDL. The MR imaging and
istology results together also likely imply that
P3533-HDL is targeting collagen fibrils as op-
osed to degraded collagen. It should be noted that
Figure 7. Intraplaque Collagen Contents
Sirius red staining of atherosclerotic plaques in aortic vessel wal
The bright ﬁeld images indicate the position of plaques. The col
centage of collagen-positive area in the plaques (n  5). A  ad
plaque position.ather than providing an absolute amount of colla-gen, EP3533-HDL indicates a relative collagen
level in plaques by MR imaging.
The different trends of macrophage and collagen
contents during plaque regression were found to be
correlated with the in vivo MR signals of aortic
vessel walls using HDL and EP3533-HDL as
contrast agents (Fig. 8). The correlations indicated
the MR signals from aortic vessel walls are most
likely reflecting the macrophage and collagen con-
tents. Therefore, collagen-specific EP3533-HDL
nanoparticles can be used to visualize the collagen
content noninvasively in vivo and thus to monitor
the characteristics that are taken to indicate the
stabilization of human atherosclerotic plaques after
therapeutic intervention.
HDL nanoparticles were found to be mainly
colocalized with CD68 macrophages at both
baseline (day 0) (Online Fig. 1) and day 28 of
regression (Fig. 5A). These results are consistent
with our previous findings in several other mouse
models (22–25). We also observed that not all
HDL nanoparticles are associated with macro-
phages, which may be due to the retention of HDL
by proteoglycans, especially biglycan and perlecan
(34–35) from the association of apolipoprotein A-I
in the lipid pools (36–38) and around necrotic cores
(A) day 0 and day 28 in (B) regression and (C) control groups.
n containing area is bright under polarized light. (D) The per-
titia position; L  lumen position; M  media position; P ls at
lage
ven(39) in atherosclerotic plaques. Interestingly, at
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382baseline (day 0), EP3533-HDL was also found to
be associated with CD68 macrophages and had a
ow association with collagen type I (Online Fig. 1).
This could be due to several reasons. First, activated
high levels of macrophages in plaques at day 0 could
take up EP3533-HDL through nonspecific endo-
cytosis or phagocytosis. Second, conjugation of
EP3533 cannot fully block HDL function, leading
to off-target macrophage association. Third, the
very low content of collagen results in little inter-
action with EP3533-HDL. However, at day 28
under regression conditions, EP3533-HDL was
found to be associated with collagen type I–rich
areas inside plaque due to strong binding to colla-
gen (Fig. 2A) and the readily accessible collagen
contents inside plaque (Figs. 7B and 7D), but it was
not found to be associated with CD68 macro-
hages due to low macrophage content (Figs. 6B
nd 6D) and the low possibility of access to nano-
articles. Little accumulation of EP3533-HDL was
bserved in the adventitia because the intravenously
njected nanoparticles remained primarily inside
umen and minimally reached adventitia, which
ypically has little vasa vasorum compared with
uman plaques.
C O N C L U S I O N S
We demonstrate that HDL-based nanoparticles are
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Figure 8. Correlations of MR Images With Macrophages and Co
Correlations of (A) CD68 and (B) collagen-positive areas with NER
Abbreviations as in Figures 1 and 3.sclerosis in vivo by MR to visualize not only
macrophages, but also collagen after conjugation to
HDL of collagen-specific peptides, which provides
a rerouting strategy. MR signal enhancements of
atherosclerotic plaques in aortic vessel walls after
HDL and EP3533-HDL injections in Reversa
mice were correlated with macrophage and col-
lagen contents, respectively. By combination of
imaging macrophage and collagen contents, the
stabilization process of atherosclerotic plaques
can be monitored and evaluated in vivo under
regression conditions.
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